SYNAIRGEN PLC
SNG | IL
Overview
Corporate Details
- ISIN(s):
- GB00B0381Z20
- LEI:
- 213800IMMTOPPDF8HD24
- Country:
- United Kingdom
- Address:
- MAILPOINT 810 LEVEL F, SO16 6YD SOUTHAMPTON
- Website:
- https://www.synairgen.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Synairgen plc is a specialist respiratory biotechnology company focused on drug discovery and development. Its primary initiative is the development of SNG001, an inhaled formulation of interferon beta (IFN-β), as a potential broad-spectrum, host-directed antiviral treatment. The company's therapeutic focus is on severe viral lung infections that lead to hospitalization, including those caused by influenza, RSV, and coronaviruses. Founded in 2003 as a spin-off from the University of Southampton, Synairgen aims to address the unmet need for effective treatments by delivering its investigative therapy directly to the lungs, the primary site of infection.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for SYNAIRGEN PLC.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-16 08:00 |
Board/Management Information
Board and Executive Leadership Changes
|
English | 9.8 KB | |
| 2025-03-28 15:21 |
Post-Annual General Meeting Information
Result of General Meeting
|
English | 18.6 KB | |
| 2025-03-11 08:00 |
Pre-Annual General Meeting Information
Proposed cancellation of trading on AIM
|
English | 76.3 KB | |
| 2025-01-17 13:55 |
Major Shareholding Notification
Holding(s) in Company
|
English | 51.8 KB | |
| 2025-01-16 16:42 |
Board/Management Information
Martin Murphy appointed as Non-Executive Director
|
English | 17.9 KB | |
| 2025-01-16 16:42 |
Post-Annual General Meeting Information
Result of General Meeting and Total Voting Rights
|
English | 13.5 KB | |
| 2025-01-15 18:37 |
Share Issue/Capital Change
£18m raised to fund Phase 2 INVENT clinical trial
|
English | 14.8 KB | |
| 2024-12-20 08:00 |
Share Issue/Capital Change
Proposed Fundraising
|
English | 398.7 KB | |
| 2024-10-30 19:09 |
Share Issue/Capital Change
Exercise of Share Options and Total Voting Rights
|
English | 10.5 KB | |
| 2024-10-10 18:05 |
Post-Annual General Meeting Information
Results of AGM and Appointment of New Chairman
|
English | 10.8 KB | |
| 2024-09-26 08:00 |
Interim Report
Interim Results
|
English | 143.5 KB | |
| 2024-09-18 08:00 |
Board/Management Information
Appointment of New Chairman and Notice of AGM
|
English | 17.7 KB | |
| 2024-09-05 08:00 |
Board/Management Information
Board Change
|
English | 11.1 KB | |
| 2024-06-27 08:00 |
Earnings Release
2023 Full Year Results
|
English | 129.1 KB | |
| 2023-11-15 08:00 |
Share Issue/Capital Change
Grant of Options
|
English | 28.7 KB |
Automate Your Workflow. Get a real-time feed of all SYNAIRGEN PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for SYNAIRGEN PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
